|
SECURITY: JNJ (Common)
EXCHANGE: New York Stock Exchange CURRENCY: US Dollar
Johnson & Johnson,
employing approximately 110,300 people worldwide, is engaged in the manufacture
and sale of a broad range of products in the health care field in many
countries of the world. Johnson & Johnson's primary interest, both
historically and currently, has been in products related to health and
well-being. Johnson & Johnson was organized in the State of New Jersey
in 1887.
Fondé en 1887,
Johnson & Johnson est l'un des premiers groupes pharmaceutiques mondiaux.
- produits pharmaceutiques
. Johnson & Johnson développe et commercialise des médicaments
destinés au traitement des pathologies suivantes : maladies cardio-vasculaires,
oncologie, maladies gastro-intestinales, immunologie, neurologie, dermatologie,
contraception ...
- produits professionnels
. J&J développe, fabrique et commercialise des produits et équipements
médicaux destinés aux professionnels de la santé :
systèmes de diagnostics, produits orthopédiques, produits
de gynécologie, matériel chirurgical, ...
-produits de grande
consommation : médicaments OTC, nutrition, soins de la personne
(marques RoC, Neutrogena, etc.), ophtalmologie (1er producteur mondial
de lentilles de contacts avec la marque Acuvue), hygiène féminine,
soins bébé, ...
http://www.jnj.com
Johnson
& Johnson Reports 2009 Fourth-Quarter and Full-Year Results:
--2009
Fourth-Quarter Sales of $16.6 Billion increased 9.0%; EPS was $0.79 --2009
Full-Year Sales of $61.9 Billion decreased 2.9%; Full-Year EPS was $4.40
--Excluding Special Items, 2009 Fourth-Quarter EPS was $1.02, an increase
of 8.5% --And 2009 Full-Year EPS was $4.63, an increase of 1.8%*
NEW
BRUNSWICK, N.J., Jan 26, 2010 /PRNewswire via COMTEX News Network/ -- Johnson
& Johnson today announced sales of $16.6 billion for the fourth quarter
of 2009, an increase of 9.0% as compared to the fourth quarter of 2008.
Operational growth was 4.5% and currency contributed 4.5%. Domestic sales
were up 2.6%, while international sales increased 15.6%, reflecting operational
growth of 6.4% and a positive currency impact of 9.2%. Worldwide sales
for the full-year 2009 were $61.9 billion, a decrease of 2.9% over 2008.
Operational results declined 0.3% and the negative impact of currency was
2.6%. Domestic sales declined 4.4%, while international sales declined
1.4%, reflecting operational growth of 3.9% and a negative currency impact
of 5.3%.
Net
earnings and diluted earnings per share for the fourth quarter of 2009
were $2.2 billion and $0.79 respectively. Fourth quarter 2009 net earnings
included an after-tax restructuring charge of $852 million and an after-tax
gain of $212 million representing the net impact of litigation matters.
Fourth quarter 2008 net earnings included special items related to in-process
research and development charges of $141 million with no tax benefit and
an after-tax gain of $229 million representing the net impact of litigation
matters. Excluding these special items, net earnings for the current quarter
were $2.8 billion and diluted earnings per share were $1.02, representing
increases of 8.4% and 8.5%, respectively, as compared to the same period
in 2008.*
Net
earnings and diluted earnings per share for the full-year 2009 were $12.3
billion and $4.40. Full-year 2009 net earnings included an after-tax restructuring
charge of $852 million and an after-tax gain of $212 million representing
the net impact of litigation matters. Full-year 2008 net earnings included
special items related to in-process research and development charges of
$181 million with no tax benefit and an after-tax gain of $229 million
representing the net impact of litigation matters. Excluding these special
items, net earnings for the full-year 2009 were $12.9 billion. Diluted
earnings per share for the full-year 2009 were $4.63, representing an increase
of 1.8%, as compared with the full-year in 2008.*
The
Company announced earnings guidance for full-year 2010 of $4.85 to $4.95
per share, which excludes the impact of special items.
"In
a year of tremendous challenge, we maintained our long-term focus while
delivering solid results -- a great tribute to the employees of Johnson
& Johnson," said William C. Weldon, Chairman and Chief Executive Officer.
"We made important investments in acquisitions, strategic partnerships
and launches of recently-approved innovative products while preserving
our financial flexibility to continue to invest in innovation. This positions
us well for continued leadership and growth in global health care as we
enter 2010."
Worldwide
Consumer sales of $15.8 billion for the full-year 2009 represented a decrease
of 1.6% over the prior year with operational growth of 2.0% and a negative
currency impact of 3.6%. Domestic sales decreased 1.4%; international sales
decreased 1.7%, which reflected operational growth of 4.7% and a negative
currency impact of 6.4%.
Primary
contributors to operational growth included NEUTROGENA(R), AVEENO(R) and
the Dabao skin care products; international sales of LISTERINE(R) antiseptic
mouthrinse; SPLENDA(R) No Calorie Sweetener; and sales from the acquisition
of Vania Expansion SNC. Sales growth was negatively impacted due to the
initial build of inventory by the trade related to the 2008 launch of Zyrtec.
Worldwide
Pharmaceutical sales of $22.5 billion for the full-year 2009 represented
a decrease of 8.3% versus the prior year with an operational decline of
6.1% and a negative impact from currency of 2.2%. Domestic sales decreased
12.1%; international sales decreased 2.6%, which reflected an operational
increase of 3.0% and a negative currency impact of 5.6%.
Johnson
& Johnson Reports 2009 Third-Quarter Results:
Sales
of $15.1 Billion Decreased 5.3% Versus 2008 Third Quarter
EPS
of $1.20 increased 2.6% Versus 2008 Third Quarter
NEW
BRUNSWICK, N.J., Oct 13, 2009 /PRNewswire-FirstCall via COMTEX News Network/
-- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.1 billion
for the third quarter of 2009, a decrease of 5.3% as compared to the third
quarter of 2008. Operational results declined 2.8% and the negative impact
of currency was 2.5%. Domestic sales declined 8.1%, while international
sales declined 2.5%, reflecting operational growth of 2.4% and a negative
currency impact of 4.9%.
Net
earnings and diluted earnings per share for the third quarter of 2009 were
$3.3 billion and $1.20, respectively, representing increases of 1.1% and
2.6%, as compared to the same period in 2008. The Company raised its earnings
guidance for full-year 2009 to $4.54 - $4.59 per share, which excludes
the impact of special items.
"We
continue to successfully manage our broad base of businesses and deliver
solid earnings despite the impact of patent expirations and the challenges
posed by the current economic environment," said William C. Weldon, Chairman
and Chief Executive Officer. "We completed multiple acquisitions and strategic
collaborations and received several new product approvals in the quarter
that will benefit patients worldwide and drive future growth."
Worldwide
Consumer sales of $4.0 billion for the third quarter represented a decrease
of 2.7% versus the prior year with an increase of 1.1% operationally and
a negative impact from currency of 3.8%. Domestic sales decreased 4.4%;
international sales decreased 1.4%, which reflected an operational increase
of 5.2% and a negative currency impact of 6.6%.
Contributing
to operational sales growth during the quarter were sales of Dabao skin
care products; AVEENO(R) skin care products; SPLENDA(R) No Calorie Sweetener;
Le Petit Marseillais(R) beauty care products; and LISTERINE(R) antiseptic
mouthrinse. Other growth drivers were sales from the acquisition of Vania
Expansion SNC.
Worldwide
Pharmaceutical sales of $5.3 billion for the third quarter represented
a decrease of 14.1% versus the prior year with an operational decline of
11.9% and a negative impact from currency of 2.2%. Domestic sales decreased
19.2%; international sales decreased 7.1%, which reflected an operational
decrease of 1.9% and a negative currency impact of 5.2%.
REMICADE(R)
(infliximab), a biologic approved for the treatment of a number of immune
mediated inflammatory diseases, demonstrated solid sales performance during
the quarter. Several other pharmaceutical products had strong growth including
PREZISTA(R) (darunavir), a treatment for HIV; VELCADE(R) (bortezomib),
a treatment for multiple myeloma; and RISPERDAL(R) CONSTA(R) (risperidone)
Long-Acting Treatment, an antipsychotic medication. Sales results of TOPAMAX(R)
(topiramate), an antiepileptic and a treatment for migraine, and RISPERDAL(R)
(risperidone), an antipsychotic medication, were negatively impacted by
generic competition. ...
Johnson
& Johnson Reports 2009 Second-Quarter Results:
See
text copy below:
Johnson
& Johnson Reports 2009 Second-Quarter Results:
--Sales
of $15.2 Billion Decreased 7.4% Versus 2008 Second Quarter --EPS of $1.15
Decreased 2.5%* Versus 2008 Second Quarter, Excluding 2008 Special Items
NEW
BRUNSWICK, N.J., July 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/
-- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.2
billion for the second quarter of 2009, a decrease of 7.4% as compared
to the second quarter of 2008. Operational results declined 1.4% and the
negative impact of currency was 6.0%. Domestic sales declined 6.7%,
while international sales declined 8.0%, reflecting operational growth
of 3.9% and a negative currency impact of 11.9%.
Net
earnings and diluted earnings per share for the second quarter of 2009
were $3.2 billion and $1.15, respectively. The second quarter of 2008 included
an after-tax in-process research and development charge of $40 million.
Excluding this charge, net earnings for the quarter and diluted earnings
per share represent decreases of 4.7% and 2.5%, respectively, as compared
to the same period in 2008.* The Company confirmed its earnings guidance
for full-year 2009 of $4.45 - $4.55 per share, which excludes the
impact of special items.
"I
am proud of the accomplishments of our people in continuing to deliver
very solid operational results in light of the significant impacts of patent
expirations and the economic environment," said William C. Weldon, Chairman
and Chief Executive Officer. "Our investments through internal research
and development, strategic partnerships and acquisitions have allowed us
to build what is considered by many to be one of the best pipelines in
our industry. We will continue to invest in our portfolio of innovative
products to meet the needs of patients and consumers around the world."
Worldwide
Consumer sales of $3.9 billion for the second quarter represented a decrease
of 4.5% versus the prior year with an increase of 3.1% operationally and
a negative impact from currency of 7.6%. Domestic sales increased 0.8%;
while international sales decreased 8.4%, which reflected an operational
increase of 4.7% and a negative currency impact of 13.1%.
LISTERINE(R)
antiseptic mouthrinse and the skin care lines of NEUTROGENA(R) and AVEENO(R)
contributed to operational sales growth during the quarter. Other growth
drivers were sales from the recently completed acquisition of the French
company Vania Expansion SNC.
Worldwide
Pharmaceutical sales of $5.5 billion for the second quarter represented
a decrease versus the prior year of 13.3% with an operational decline of
8.5% and a negative impact from currency of 4.8%. Domestic sales decreased
16.4%; while international sales decreased 8.7%, which reflected an operational
increase of 3.3% and a negative currency impact of 12.0%.
REMICADE(R)
(infliximab), a biologic approved for the treatment of a number of immune
mediated inflammatory diseases; PREZISTA(R) (darunavir), a treatment for
HIV; VELCADE(R) (bortezomib), a treatment for multiple myeloma; and CONCERTA(R)
(methylphenidate HCI), a treatment for attention deficit hyperactivity
disorder, had strong operational sales performance during the quarter.
Sales results of TOPAMAX(R) (topiramate), an anti-epileptic, and RISPERDAL(R)
(risperidone), an antipsychotic medication, were negatively impacted by
generic competition.
During
the quarter, the U.S. Food and Drug Administration (FDA) approved SIMPONI(TM)
(golimumab) for the treatment of adults with moderately to severely active
rheumatoid arthritis in combination with methotrexate, active psoriatic
arthritis with or without methotrexate, and active ankylosing spondylitis.
The FDA also approved the Supplemental New Drug Applications (sNDAs) for
the use of RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment as
both monotherapy and adjunctive therapy to lithium or valproate in the
maintenance treatment of Bipolar I Disorder. The Drug Enforcement Administration
(DEA) issued their final ruling and placed NUCYNTA(TM) (tapentadol) CII
immediate release tablets for the relief of moderate to severe acute pain
in patients 18 years of age or older into Schedule II of the Controlled
Substances Act. The product is now available to patients.
The
Company also announced a definitive agreement to acquire Cougar Biotechnology,
a development stage biopharmaceutical company with a specific focus on
oncology, for approximately $1.0 billion in a cash tender offer.
On July 9, 2009, the acquisition of Cougar Biotechnology was completed.
On July 2, 2009, the Company announced a definitive agreement with Elan
Corporation, plc. whereby Johnson & Johnson will acquire substantially
all of the assets and rights of Elan related to its Alzheimer's Immunotherapy
Program and will invest $1 billion in Elan newly issued American Depositary
Receipts (ADRs).
Worldwide
Medical Devices and Diagnostics sales of $5.9 billion for the second quarter
represented a decrease of 3.1% versus the prior year with an operational
increase of 2.9% and a negative currency impact of 6.0%. Domestic sales
increased 1.9%; while international sales decreased 7.2%, which reflected
an operational increase of 3.7% and a negative currency impact of 10.9%.
Primary
contributors to the operational growth included Ethicon's surgical care
products; Ortho-Clinical Diagnostics' professional products; Ethicon Endo-Surgery's
minimally invasive products; and DePuy's orthopaedic joint reconstruction,
spine, and sports medicine businesses. Also contributing to growth were
sales of products acquired as part of the completed acquisition of Mentor
Corporation, a leading supplier of medical products for the global aesthetic
market. This growth was partially offset by lower sales in the Cordis franchise,
reflecting new competitive entries in the drug-eluting stent market as
well as the 2008 divestiture of the Professional Wound Care products in
our Ethicon business.
Johnson
& Johnson has added a new press release to the Investor Relations section
of the Company's Web site
NEW
BRUNSWICK, N.J., July 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/
-- Johnson & Johnson (NYSE: JNJ) today announced it has successfully
completed its acquisition of Cougar Biotechnology, Inc., a development
stage biopharmaceutical company with a specific focus on oncology.
Johnson
& Johnson's tender offer for shares of Cougar Biotechnology common
stock expired at 5 p.m. Eastern Daylight Time (EDT) yesterday with approximately
20,148,930 shares tendered, representing approximately 95.9% of Cougar
Biotechnology's outstanding common stock. The acquisition was completed
yesterday through what is known as a "short-form" merger, without a vote
or meeting of Cougar Biotechnology's remaining shareholders.
Cougar
Biotechnology currently is conducting two Phase III trials for abiraterone
acetate, a late stage, first-in-class compound for the treatment of prostate
cancer. The first Phase III trial is testing abiraterone acetate in patients
with metastatic, castration-resistant prostate cancer who have progressed
after docetaxel-based chemotherapy has failed. The second Phase III trial
is studying abiraterone acetate in patients with metastatic, castration-resistant
prostate cancer who have yet to receive chemotherapy.
One
in six men will be diagnosed with prostate cancer in his lifetime, and
the disease accounts for 10 percent of cancer-related deaths in the United
States.
Cougar
Biotechnology now operates as a wholly-owned subsidiary of Johnson &
Johnson and will work with Ortho Biotech Oncology Research & Development,
a unit of Centocor Research & Development, Inc., a Johnson & Johnson
company.
"With
the acquisition of Cougar Biotechnology and its talented team, we have
strengthened our position in the global oncology market and our efforts
to provide a meaningful difference in the lives of millions of patients
worldwide," said William N. Hait, M.D., Ph.D., Global Therapeutic Head,
Oncology, Ortho Biotech Oncology Research & Development. "Abiraterone
acetate now becomes one of many new treatments we are developing, which
we hope will change the course of cancer treatment by targeting cancer
cells and the tumor microenvironment."
About
Johnson & Johnson
Caring
for the world, one person at a time ... inspires and unites the people
of Johnson & Johnson. We embrace research and science -- bringing innovative
ideas, products and services to advance the health and well-being of people.
Our 119,000 employees at more than 250 Johnson & Johnson companies
work with partners in health care to touch the lives of over a billion
people every day, throughout the world |
